CooperVision to Present New Scientific Findings on Presbyopia Correction and Myopia Management at Academy '23

SAN RAMON, Calif., October 9, 2023—CooperVision's global leadership in addressing both presbyopia correction and myopia progression will take center stage at the American Academy of Optometry 2023 Annual Meeting, which opens this week in New Orleans. The company's researchers and partners are scheduled to present multiple scientific posters whose findings will aid how eye care professionals (ECPs) evaluate and prescribe a range of contact lenses to optimize patient experience and practice success.

"Over recent years, CooperVision has established a major presence on the scientific program at Academy. This reflects a deep commitment to extend research and development efforts well beyond commercializing innovative products. Once our contact lenses reach the marketplace, the team's work continues to help build further confidence and expertise with ECPs and staff, including in selection, fitting, and wearer education," said Francis Erard, the company's Vice President of Research & Development.

New Dimensions in Managing Presbyopia

Known for its expertise in developing sophisticated multifocal contact lenses that consider patient lifestyles as well as day-to-day practice needs, CooperVision will provide a series of unique insights designed to further advance prescription options and care for presbyopes.

Seeking to help understand why contact lens drop-out rates may be higher among presbyopic patients compared to single vision wearers, *Task-Based Evaluations of Two Daily Disposable Soft Multifocal Lenses* (Luensmann D, et al) investigated subjective comfort and task-related vision performance. The randomized, subject masked, cross-over study of 51 habitual wearers used a Likert rating scale for statements surrounding feel and comfort, vision in different settings and situations (e.g., driving, laptop use), and reliability. Both lenses, including MyDay® multifocal, largely met or exceeded the wearers' task-based needs, suggesting that a multifocal lens deemed comfortable combined with good situational performance may protect against real world drop-out.

Achieving fit success without extended chair time may increase the likelihood of practices prescribing multifocal contact lenses. Investigators theorized that earlier prediction of patient trial outcomes could aid ECP confidence and subsequent multifocal adoption. *Predictability of Multifocal Contact Lens Success at Dispense* (Lazon de la Jara P, et al) combined data from three studies to quantify the relationship between the initial reaction to lenses at dispensing and predictability of overall vision satisfaction and intention to purchase after one week of wear. Among 210 participants, overall vision satisfaction on dispensing was a powerful predictor of both overall vision satisfaction ($p < 0.001$) and intention to purchase ($p < 0.001$) at one week, inferring that initial patient subjective assessments are a clinically useful indicator of longer-term successful multifocal wear.

CooperVision also sought to help current fitters of clariti® 1 day multifocal contact lenses assess switching patients into the newer MyDay® multifocal lens with Aquaform® Technology and the unique Binocular Progressive System™. *Investigation of Ease of Fit to a Different Daily Disposable Multifocal Soft Lens* (Woods J, et al) enrolled 60 wearers in a crossover, subject-masked study, each of whom wore optimal powers for two weeks of each product (post-adjustment if required). Subjects reported the transition to be easy, resulting in clear vision and through the wear period, with most stating that MyDay® multifocal comfort and vision experiences met or exceeded their needs.

Significant Myopia Control and Management Insights

During Academy 2023, CooperVision will build upon its reputation for evidence-based approaches to myopia control and management through several studies.

Most prominent is *Subjective Vision Experience in Soft Myopia Control Contact Lenses by Age* (Guthrie S, et al), which compared short-term vision of preteens and teens between two lens designs. 26 children aged 8-15 years who had no prior history of contact lens wear or recent myopia control interventions participated in a single-visit, double-masked trial with study lenses—MiSight® 1 day and ACUVUE® Abiliti™ 1-Day—randomly fit and worn contralaterally. MiSight® 1 day was preferred by both groups for better distance vision measured subjectively and objectively, as well as for near visual acuity. Likewise, more preteens and teens chose MiSight® 1 day as their overall lens preference after one hour of wear, citing vision as the primary reason. While teens had an equivalent objective vision experience to the preteens for both lenses, they were more likely to subjectively rate that experience lower than preteens. This indicates that teenagers may offer a more critical assessment of their vision, which ECPs should make note of for interactions with patients as they age.

With its growing prominence in China, MiSight® 1 day was also the subject of *Short-Term Clinical Performance and Vision Quality of Dual-Focus Soft Contact Lenses in Myopic Children in Shanghai, China* (Zeng L, et al). 33 myopic children who were new to soft contact lens wear and with no prior myopia control intervention were fit with MiSight® 1 day, then assessed after one week and one month. The lens demonstrated good clinical performance and stable vision quality across both timeframes.

Adding an additional study site and more participants to data first shared at the 2023 BCLA Clinical Conference, *Software Guided Orthokeratology Fitting Success* (Luensmann D., et al.) used CooperVision's Visavy™ platform to provide recommended parameters for Paragon® CRT or CRT Dual Axis lenses. The experiences of 54 participants across four study sites were analyzed, with topography data, subjective refraction and white-to-white corneal diameter entered into the software. Only four eyes (<4%) from three subjects required a lens parameter change after the initial Visavy™ recommendation. This >96% first fit success rate reflects probable time-saving and patient experience benefits of the new decision support technology for ortho-k practices.

CooperVision is also a sponsor of the *Myopia in Practice (MIP) Study* presented in New Orleans as part of the American Academy of Optometry Fellows Doing Research special interest group.

The company's studies shared at Academy were conducted in conjunction with the Centre for Ocular Research & Education (CORE), Waterloo, Ontario, Canada; Ocular Technology

Group International (OTGi), London, England; and Eye & ENT Hospital, Fudan University, Shanghai, China.

Additional study information can be viewed within the Academy ’23 mobile app, in person at the COPE-accredited poster sessions in the New Orleans Ernest N. Morial Convention Center, and on CooperVision.com.

# # #

U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.

About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Media Contact
Mike McDougall, APR, Fellow PRSA, FAAO, McDougall Communications for CooperVision
mike@mcdougallpr.com or +1-585-545-1815